Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial
| Status: | Completed |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/3/2014 |
| Start Date: | March 2012 |
| End Date: | May 2012 |
| Contact: | James Januzzi, MD |
| Email: | jjanuzzi@partners.org |
| Phone: | 617-726-3443 |
Biomarkers Plus Bioimpedance Vector Analysis to Predict Cardiorenal Syndrome Onset and Prognosis in Patients With Acutely Decompensated Heart Failure: Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial
The purpose of this study is to evaluate the ability of a non-invasive monitor that measures
how much fluid is in the body as well as various blood tests for their ability to predict
worsening kidney function in patients with heart failure.
how much fluid is in the body as well as various blood tests for their ability to predict
worsening kidney function in patients with heart failure.
Our specific aims are to:
1. Evaluate the individual and collective ability of pro-B type natriuretic peptide
(NT-pro-BNP), soluble (s)ST2, neutrophil gelatinase-associated lipocalin (NGAL), and
bioelectrical impedance vector analysis (BIVA) for predicting in-hospital worsening
renal function (WRF) in patients evaluated in emergency department (ED)with acutely
decompensated heart failure (ADHF)compared to a model of clinical variables alone.
2. Evaluate the individual and collective ability of NT-proBNP, sST2, NGAL, and BIVA for
identifying the correct cause of in-hospital WRF in patients evaluated in the ED with
ADHF.
3. Evaluate the individual and collective ability of NT-pro-BNP, sST2, NGAL, and BIVA for
predicting outcomes (all-cause death, all-cause re-hospitalization, initiation of renal
replacement therapy by 180 days) in patients with ADHF.
1. Evaluate the individual and collective ability of pro-B type natriuretic peptide
(NT-pro-BNP), soluble (s)ST2, neutrophil gelatinase-associated lipocalin (NGAL), and
bioelectrical impedance vector analysis (BIVA) for predicting in-hospital worsening
renal function (WRF) in patients evaluated in emergency department (ED)with acutely
decompensated heart failure (ADHF)compared to a model of clinical variables alone.
2. Evaluate the individual and collective ability of NT-proBNP, sST2, NGAL, and BIVA for
identifying the correct cause of in-hospital WRF in patients evaluated in the ED with
ADHF.
3. Evaluate the individual and collective ability of NT-pro-BNP, sST2, NGAL, and BIVA for
predicting outcomes (all-cause death, all-cause re-hospitalization, initiation of renal
replacement therapy by 180 days) in patients with ADHF.
Inclusion Criteria:
- Dyspnea thought to be due to ADHF
- NYHA class III or IV symptoms
Exclusion Criteria:
- renal failure requiring renal replacement therapy rior to enrollment
- unable or unwilling to participate
- > 6 hours from first dose of intravenous diuretic
We found this trial at
1
site
Click here to add this to my saved trials
